The effects of accident pregnancy CHB patients’ reproductive age on their offspring during entecavir antiviral therapy: an observational study

BACKGROUND The study aimed to investigate the effects of accident pregnancy CHB ([Chronic Hepatitis](http://www.baidu.com/link?url=bHvatnxYLAbcjw_Xc6Po2pWn-j8Cw8-V01IB9mGZLaFAS63z43BHW-ZECROGrZEeOOjAJDQ1ICVf3GKfmBN7GfifgilBQbCFlMWNkzl8Daa0vxsvMG9VXI7dE_T8X4Tf) B) patients’ reproductive age on their offspring during entecavir (ETV) antiviral therapy due to lacking related data. METHODS 112 couples were divided into case and control groups. 53 couples who had accident pregnancies while receiving long-term ETV antiviral medication were recruited for the case group. 53 of them, including HBsAg-positive dads (11/53, 20.7%). The control group comprised 59 couples who became pregnant accidentally while receiving long-term TDF antiviral treatment. Of them,59 couples, including HBsAg-positive dads (25.4%, 15/59), All mothers persisted in their pregnancies in the case group, and ETV was promptly replaced with TDF. Every mother remained pregnant and continued to use TDF in the control group. All newborns received immunoprophylaxis. RESULTS The maternal and baby safety profiles, including the prevalence of congenital disabilities, were comparable across the case and control groups at delivery. In addition, no unusual indications or symptoms of the newborns were noted during the follow-up intervals of 28, 48, and 96 weeks postpartum. The current study had a 100% success rate in preventing mother-to-child transmission. CONCLUSIONS Initiating ETV or TDF in early and middle pregnancy seems to be safe for both mothers and infants and is effective. Important data from our investigation support using ETV in early-mid gestational accident pregnancies and the prompt substitution of TDF antiviral medication for ETV. The pregnancy was not needed to be terminated.